4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis.

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          After in vitro tests, a tracer dose of cisplatin was administered to an anuric cancer patient. Plasma total platinum levels were monitored as a function of time, as was filterable platinum elimination by hemofiltration dialysis. Based on the derived pharmacokinetic parameters, the patient was later given 50-mg doses of cisplatin, once as a single agent, then four times in combination with doxorubicin, VM-26, and cyclophosphamide. Plasma levels could be fitted by a sum of three exponentials after the infusion was stopped. The mean corresponding half-lives are 30 minutes, 6 hours, and 5 days. Depending on the rate of infusion, plasma peaks ranged between 1.1 micrograms/ml (5.7 X 10(-6) M) and 2.27 micrograms/ml (1.16 X 10(-5) M). During the hemofiltration process immediately following the infusion, the elimination rate was first-order, with a mean half-life of 60 minutes. The mean amount eliminated during the first hemofiltration session was 8% of the dose, decreasing to about 3% on Days 2 and 3. A partial tumor response was observed after two treatment courses, evidenced by the relief of abdominal pain and bowel obstruction episodes and a 50% decrease in peritoneal metastases.

          Related collections

          Author and article information

          Journal
          Cancer Treat Rep
          Cancer treatment reports
          0361-5960
          0361-5960
          July 1 1981
          : 65
          : 7-8
          Article
          7195773
          9301e58b-44ff-4fb7-8fab-623fe0c92254
          History

          Comments

          Comment on this article